2025 Q3 -tulosraportti
22 päivää sitten42 min
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
34 552
Myynti
Määrä
87 375
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 000 | - | - | ||
| 13 452 | - | - | ||
| 13 449 | - | - | ||
| 6 551 | - | - | ||
| 16 670 | - | - |
Ylin
0,24VWAP
Alin
0,201VaihtoMäärä
6,1 27 953 761
VWAP
Ylin
0,24Alin
0,201VaihtoMäärä
6,1 27 953 761
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 28 028 885 | 28 028 885 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 28 028 885 | 28 028 885 | 0 | 0 |
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 24.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 26.11. | |
| 2025 Q2 -tulosraportti | 28.8. | |
| 2025 Q1 -tulosraportti | 14.5. | |
| 2024 Q4 -tulosraportti | 25.2. | |
| 2024 Q3 -tulosraportti | 27.11.2024 |
Datan lähde: Quartr, FactSet
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·6 t sitten · MuokattuThe company keeps draining money from the company and us shareholders! That's a damn disgrace after we have coughed up and then they choose to do a reverse stock split - the entire board should be fired! This venture is fraud, nothing else….
·1 päivä sittenNew, Interesting article about early detection in Nature. Immunovia is mentioned, among others. https://www.nature.com/articles/d41586-025-03945-1
·1 päivä sittenPancreasure is mentioned in the article as you say but perhaps not in a particularly positive way? Both Avantect and PancreaSure, which was developed by Immunovia in Lund, Sweden, are commercially available in the United States. But they aren’t widely used. "Insurance doesn’t pay for them because the level of evidence that’s been generated thus far is not sufficient,"·1 päivä sitten · MuokattuNo, it's probably neutral. Then there's also some general discussion about markers, most likely Immunovia should be included among these 3 - maybe some information about that will come in the future: "The next test for many of these assays is what’s known as a biomarker bake-off — a competition that allows head-to-head comparisons. So far, the US National Cancer Institute (NCI) in Bethesda, Maryland, has helped to coordinate two, and a third, which includes PAC-MANN, is under way. During the bake-off, groups of researchers that have developed assays all receive the same samples. Each group runs its test and reports back which samples it has identified as cases of pancreatic cancer and which are not. Results of the second bake-off haven’t yet been published, but \“some of the biomarkers seem to be very promising. They are doing better than CA 19-9\”, says Sudhir Srivastava, head of the NCI’s cancer biomarkers research group."
·1 päivä sitten · Muokattuhttps://forum.placera.se/inlagg/16221009-97dd-4d57-b29d-101e5c925839 https://forum.placera.se/bolag/immunovia From Placera-forum Nick37 20 hours ago Immunovia Immunovia is looking for people https://www.linkedin.com/posts/immunovia-ab_hello-were-continuing-to-expand-and-grow-activity-7405035205431816192-BUTk?utm_source=li_share&utm_content=feedcontent&utm_medium=g_mb_web&utm_campaign=copy Hello! We’re continuing to expand and grow, and we’re thrilled to announce that we’re hiring a Medical Affairs Specialist to join our amazing team! 🎉 If you’re interested or know someone who would… | Immunovia AB Hello! We’re continuing to expand and grow, and we’re thrilled to announce that we’re hiring a Medical Affairs Specialist to join our amazing team! 🎉 If you’re interested or know someone who would… | Immunovia AB Hello! We’re continuing to expand and grow, and we’re thrilled to announce that we’re hiring a Medical Affairs Specialist to join our amazing team! 🎉 If you’re interested or know someone who would be a fantastic fit, please use the link below to apply. We’re excited to bring another incredible team member on board! https://lnkd.in/eruxC66q www.linkedin.com- ·1 päivä sitten · MuokattuCheck the title of this news. It is and remains a TOTALLY misleading headline. Ugh 🤦🙈 But it's made by AI then, for Nordnet. Ugh, sharpen up Nordnet https://www.nordnet.no/market/news/ed7b9f6e-77e7-425b-b0f3-11b4fdf8ad87 "Immunovia secures Medicare reimbursement 26 Nov. 16:15 ∙ News Summary (AI) Immunovia has achieved significant milestones, including securing a national Medicare reimbursement rate of $897 for its PancreaSure test, effective from January 2026. This decision is a critical step towards full Medicare coverage and enables future billing of insurance companies. At the same time, the company announced the publication of an important clinical study validating PancreaSure's effectiveness in early detection of pancreatic cancer, along with reporting its Q3 2025 financial results which showed reduced losses despite lower revenues. Centers for Medicare & Medicaid Services (CMS) set a national reimbursement rate of $897 for Immunovia's PancreaSure test, effective from January 1, 2026. This reimbursement represents the second of three steps towards full Medicare coverage, allowing the company to bill insurance providers from 2026. The VERIFI clinical study, published in Current Oncology, confirmed PancreaSure's effectiveness in detecting stage 1 and 2 pancreatic cancer in high-risk individuals with 76.5 % sensitivity and 87.8 % specificity. Immunovia reported an operating loss of -25.1 million SEK for Q3 2025 (compared to -31.2 million SEK year-over-year) and a net loss of -29.7 million SEK (compared to -51.1 million SEK year-over-year). Net sales for Q3 2025 were 0.1 million SEK, down from 0.2 million SEK the previous year, with cash and cash equivalents of 26.6 million SEK."
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
22 päivää sitten42 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·6 t sitten · MuokattuThe company keeps draining money from the company and us shareholders! That's a damn disgrace after we have coughed up and then they choose to do a reverse stock split - the entire board should be fired! This venture is fraud, nothing else….
- ·1 päivä sittenNew, Interesting article about early detection in Nature. Immunovia is mentioned, among others. https://www.nature.com/articles/d41586-025-03945-1·1 päivä sittenPancreasure is mentioned in the article as you say but perhaps not in a particularly positive way? Both Avantect and PancreaSure, which was developed by Immunovia in Lund, Sweden, are commercially available in the United States. But they aren’t widely used. "Insurance doesn’t pay for them because the level of evidence that’s been generated thus far is not sufficient,"·1 päivä sitten · MuokattuNo, it's probably neutral. Then there's also some general discussion about markers, most likely Immunovia should be included among these 3 - maybe some information about that will come in the future: "The next test for many of these assays is what’s known as a biomarker bake-off — a competition that allows head-to-head comparisons. So far, the US National Cancer Institute (NCI) in Bethesda, Maryland, has helped to coordinate two, and a third, which includes PAC-MANN, is under way. During the bake-off, groups of researchers that have developed assays all receive the same samples. Each group runs its test and reports back which samples it has identified as cases of pancreatic cancer and which are not. Results of the second bake-off haven’t yet been published, but \“some of the biomarkers seem to be very promising. They are doing better than CA 19-9\”, says Sudhir Srivastava, head of the NCI’s cancer biomarkers research group."
- ·1 päivä sitten · Muokattuhttps://forum.placera.se/inlagg/16221009-97dd-4d57-b29d-101e5c925839 https://forum.placera.se/bolag/immunovia From Placera-forum Nick37 20 hours ago Immunovia Immunovia is looking for people https://www.linkedin.com/posts/immunovia-ab_hello-were-continuing-to-expand-and-grow-activity-7405035205431816192-BUTk?utm_source=li_share&utm_content=feedcontent&utm_medium=g_mb_web&utm_campaign=copy Hello! We’re continuing to expand and grow, and we’re thrilled to announce that we’re hiring a Medical Affairs Specialist to join our amazing team! 🎉 If you’re interested or know someone who would… | Immunovia AB Hello! We’re continuing to expand and grow, and we’re thrilled to announce that we’re hiring a Medical Affairs Specialist to join our amazing team! 🎉 If you’re interested or know someone who would… | Immunovia AB Hello! We’re continuing to expand and grow, and we’re thrilled to announce that we’re hiring a Medical Affairs Specialist to join our amazing team! 🎉 If you’re interested or know someone who would be a fantastic fit, please use the link below to apply. We’re excited to bring another incredible team member on board! https://lnkd.in/eruxC66q www.linkedin.com
- ·1 päivä sitten · MuokattuCheck the title of this news. It is and remains a TOTALLY misleading headline. Ugh 🤦🙈 But it's made by AI then, for Nordnet. Ugh, sharpen up Nordnet https://www.nordnet.no/market/news/ed7b9f6e-77e7-425b-b0f3-11b4fdf8ad87 "Immunovia secures Medicare reimbursement 26 Nov. 16:15 ∙ News Summary (AI) Immunovia has achieved significant milestones, including securing a national Medicare reimbursement rate of $897 for its PancreaSure test, effective from January 2026. This decision is a critical step towards full Medicare coverage and enables future billing of insurance companies. At the same time, the company announced the publication of an important clinical study validating PancreaSure's effectiveness in early detection of pancreatic cancer, along with reporting its Q3 2025 financial results which showed reduced losses despite lower revenues. Centers for Medicare & Medicaid Services (CMS) set a national reimbursement rate of $897 for Immunovia's PancreaSure test, effective from January 1, 2026. This reimbursement represents the second of three steps towards full Medicare coverage, allowing the company to bill insurance providers from 2026. The VERIFI clinical study, published in Current Oncology, confirmed PancreaSure's effectiveness in detecting stage 1 and 2 pancreatic cancer in high-risk individuals with 76.5 % sensitivity and 87.8 % specificity. Immunovia reported an operating loss of -25.1 million SEK for Q3 2025 (compared to -31.2 million SEK year-over-year) and a net loss of -29.7 million SEK (compared to -51.1 million SEK year-over-year). Net sales for Q3 2025 were 0.1 million SEK, down from 0.2 million SEK the previous year, with cash and cash equivalents of 26.6 million SEK."
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
34 552
Myynti
Määrä
87 375
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 000 | - | - | ||
| 13 452 | - | - | ||
| 13 449 | - | - | ||
| 6 551 | - | - | ||
| 16 670 | - | - |
Ylin
0,24VWAP
Alin
0,201VaihtoMäärä
6,1 27 953 761
VWAP
Ylin
0,24Alin
0,201VaihtoMäärä
6,1 27 953 761
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 28 028 885 | 28 028 885 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 28 028 885 | 28 028 885 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 24.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 26.11. | |
| 2025 Q2 -tulosraportti | 28.8. | |
| 2025 Q1 -tulosraportti | 14.5. | |
| 2024 Q4 -tulosraportti | 25.2. | |
| 2024 Q3 -tulosraportti | 27.11.2024 |
Datan lähde: Quartr, FactSet
2025 Q3 -tulosraportti
22 päivää sitten42 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 24.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 26.11. | |
| 2025 Q2 -tulosraportti | 28.8. | |
| 2025 Q1 -tulosraportti | 14.5. | |
| 2024 Q4 -tulosraportti | 25.2. | |
| 2024 Q3 -tulosraportti | 27.11.2024 |
Datan lähde: Quartr, FactSet
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·6 t sitten · MuokattuThe company keeps draining money from the company and us shareholders! That's a damn disgrace after we have coughed up and then they choose to do a reverse stock split - the entire board should be fired! This venture is fraud, nothing else….
- ·1 päivä sittenNew, Interesting article about early detection in Nature. Immunovia is mentioned, among others. https://www.nature.com/articles/d41586-025-03945-1·1 päivä sittenPancreasure is mentioned in the article as you say but perhaps not in a particularly positive way? Both Avantect and PancreaSure, which was developed by Immunovia in Lund, Sweden, are commercially available in the United States. But they aren’t widely used. "Insurance doesn’t pay for them because the level of evidence that’s been generated thus far is not sufficient,"·1 päivä sitten · MuokattuNo, it's probably neutral. Then there's also some general discussion about markers, most likely Immunovia should be included among these 3 - maybe some information about that will come in the future: "The next test for many of these assays is what’s known as a biomarker bake-off — a competition that allows head-to-head comparisons. So far, the US National Cancer Institute (NCI) in Bethesda, Maryland, has helped to coordinate two, and a third, which includes PAC-MANN, is under way. During the bake-off, groups of researchers that have developed assays all receive the same samples. Each group runs its test and reports back which samples it has identified as cases of pancreatic cancer and which are not. Results of the second bake-off haven’t yet been published, but \“some of the biomarkers seem to be very promising. They are doing better than CA 19-9\”, says Sudhir Srivastava, head of the NCI’s cancer biomarkers research group."
- ·1 päivä sitten · Muokattuhttps://forum.placera.se/inlagg/16221009-97dd-4d57-b29d-101e5c925839 https://forum.placera.se/bolag/immunovia From Placera-forum Nick37 20 hours ago Immunovia Immunovia is looking for people https://www.linkedin.com/posts/immunovia-ab_hello-were-continuing-to-expand-and-grow-activity-7405035205431816192-BUTk?utm_source=li_share&utm_content=feedcontent&utm_medium=g_mb_web&utm_campaign=copy Hello! We’re continuing to expand and grow, and we’re thrilled to announce that we’re hiring a Medical Affairs Specialist to join our amazing team! 🎉 If you’re interested or know someone who would… | Immunovia AB Hello! We’re continuing to expand and grow, and we’re thrilled to announce that we’re hiring a Medical Affairs Specialist to join our amazing team! 🎉 If you’re interested or know someone who would… | Immunovia AB Hello! We’re continuing to expand and grow, and we’re thrilled to announce that we’re hiring a Medical Affairs Specialist to join our amazing team! 🎉 If you’re interested or know someone who would be a fantastic fit, please use the link below to apply. We’re excited to bring another incredible team member on board! https://lnkd.in/eruxC66q www.linkedin.com
- ·1 päivä sitten · MuokattuCheck the title of this news. It is and remains a TOTALLY misleading headline. Ugh 🤦🙈 But it's made by AI then, for Nordnet. Ugh, sharpen up Nordnet https://www.nordnet.no/market/news/ed7b9f6e-77e7-425b-b0f3-11b4fdf8ad87 "Immunovia secures Medicare reimbursement 26 Nov. 16:15 ∙ News Summary (AI) Immunovia has achieved significant milestones, including securing a national Medicare reimbursement rate of $897 for its PancreaSure test, effective from January 2026. This decision is a critical step towards full Medicare coverage and enables future billing of insurance companies. At the same time, the company announced the publication of an important clinical study validating PancreaSure's effectiveness in early detection of pancreatic cancer, along with reporting its Q3 2025 financial results which showed reduced losses despite lower revenues. Centers for Medicare & Medicaid Services (CMS) set a national reimbursement rate of $897 for Immunovia's PancreaSure test, effective from January 1, 2026. This reimbursement represents the second of three steps towards full Medicare coverage, allowing the company to bill insurance providers from 2026. The VERIFI clinical study, published in Current Oncology, confirmed PancreaSure's effectiveness in detecting stage 1 and 2 pancreatic cancer in high-risk individuals with 76.5 % sensitivity and 87.8 % specificity. Immunovia reported an operating loss of -25.1 million SEK for Q3 2025 (compared to -31.2 million SEK year-over-year) and a net loss of -29.7 million SEK (compared to -51.1 million SEK year-over-year). Net sales for Q3 2025 were 0.1 million SEK, down from 0.2 million SEK the previous year, with cash and cash equivalents of 26.6 million SEK."
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
34 552
Myynti
Määrä
87 375
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 000 | - | - | ||
| 13 452 | - | - | ||
| 13 449 | - | - | ||
| 6 551 | - | - | ||
| 16 670 | - | - |
Ylin
0,24VWAP
Alin
0,201VaihtoMäärä
6,1 27 953 761
VWAP
Ylin
0,24Alin
0,201VaihtoMäärä
6,1 27 953 761
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 28 028 885 | 28 028 885 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 28 028 885 | 28 028 885 | 0 | 0 |